2018
Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization
Piña IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, Velazquez EJ, Pai RG, Cyrille N, Lee KL, Desvigne-Nickens P. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. Circulation 2018, 137: 771-780. PMID: 29459462, PMCID: PMC5896331, DOI: 10.1161/circulationaha.117.030526.Peer-Reviewed Original ResearchConceptsIschemic left ventricular dysfunctionLeft ventricular dysfunctionCause mortalityCardiovascular mortalitySTICH trialSurgical deathsVentricular dysfunctionCardiovascular hospitalizationRisk factorsKansas City Cardiomyopathy Questionnaire overall summary scoreHigher New York Heart Association classCardiac Operative Risk Evaluation scoreCoronary artery disease risk factorsNew York Heart Association classHigher body mass indexComposite of deathCoronary artery bypassIschemic heart failureDisease risk factorsPoor prognostic factorVentricular ejection fractionCoronary artery diseaseBody mass indexLong-term outcomesOverall summary score
2012
Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting
Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. Journal Of Electrocardiology 2012, 46: 45-50. PMID: 23063241, DOI: 10.1016/j.jelectrocard.2012.08.011.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationQuality of anticoagulationAtrial fibrillationTherapeutic rangeStroke preventionPrimary careCardiology practiceRecent large randomized control trialsNew oral anticoagulation agentsPrimary care practice patientsCardiovascular disease risk factorsOne-year periodTreatment of AFInternational normalized ratio (INR) valuesLarge randomized control trialsOral anticoagulation agentsMean therapeutic rangeOral anticoagulation therapyDisease risk factorsPrimary care practicesNovel pharmacologic agentsMulti-center studyCurrent clinical practiceRandomized control trialPrimary care groups